79 research outputs found

    Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

    Get PDF
    The value of the serum tumour marker CA 125 to date has been in the monitoring of ovarian cancer patients for response to therapy and for recurrence of disease. However, despite the availability of serial data on CA 125, the problem of interpreting a change over time is still unsolved. The aim of this study was to assess the ability of CA 125 to monitor patients with ovarian cancer during postoperative chemotherapy. 255 patients with stage IC-IV ovarian cancer were allocated to the tumour marker monitoring study. The evaluation of CA 125 information was based on the analytical imprecision, the normal intra-individual biological variation, the sampling interval, and the cut-off value. Additionally, a new assessment criterion based upon an increment of 2.5 times the baseline CA 125 concentration confirmed by a third measurement was elaborated and the utility investigated. The efficiency of CA 125 for identifying progression and non-progression during first-line chemotherapy was 91.9%. The median lead time for true positive results was 41 days. Using the new elaborated criterion the efficiency of CA 125 for identifying progression and non-progression during first-line chemotherapy was 90.5%. The median lead time for true positive results was 35 days. CA 125 gave reliable prediction of progressive disease during postoperative chemotherapy. The results indicate a high applicability of the presented progression criteria during CA 125 monitoring of patients with changing activity of ovarian cancer. © 2001 Cancer Research Campaign www.bjcancer.co

    Gender-partitioned patient medians of serum albumin requested by general practitioners for the assessment of analytical stability

    Get PDF
    AbstractBackground:Recently, the use of separate gender-partitioned patient medians of serum sodium has revealed potential for monitoring analytical stability within the optimum analytical performance specifications for laboratory medicine. The serum albumin concentration depends on whether a patient is sitting or recumbent during phlebotomy. We therefore investigated only examinations requested by general practitioners (GPs) to provide data from sitting patients.Methods:Weekly and monthly patient medians of serum albumin requested by GP for both male and female patients were calculated from the raw data obtained from three analysers in the hospital laboratory on examination of samples from those &gt;18 years. The half-range of medians were applied as an estimate of the maximum bias. Further, the ratios between the two medians were calculated (females/males).Results:The medians for male and female patients were closely related despite considerable variation due to the current analytical variation. This relationship was confirmed by the calculated half-range for the monthly ratio between the genders of 0.44%, which surpasses the optimum analytical performance specification for bias of serum albumin (0.72%). The weekly ratio had a half-range of 1.83%, which surpasses the minimum analytical performance specifications of 2.15%.Conclusions:Monthly gender-partitioned patient medians of serum albumin are useful for monitoring of long-term analytical stability, where the gender medians are two independent estimates of changes in (delta) bias: only results requested by GP are of value in this application to ensure that all patients are sitting during phlebotomy.</jats:sec

    Separate patient serum sodium medians from males and females provide independent information on analytical bias

    Get PDF
    AbstractBackground:During monitoring of monthly medians of results from patients undertaken to assess analytical stability in routine laboratory performance, the medians for serum sodium for male and female patients were found to be significantly related.Methods:Daily, weekly and monthly patient medians of serum sodium for both male and female patients were calculated from results obtained on samples from the population &gt;18 years on three analysers in the hospital laboratory. The half-range of medians was applied as an estimate of the maximum bias. Further, the ratios between the two medians were calculated.Results:The medians of both genders demonstrated dispersions over time, but they were closely connected in like patterns, which were confirmed by the half-range of the ratios of medians for males and females that varied from 0.36% for daily, 0.14% for weekly and 0.036% for monthly ratios over all instruments.Conclusions:The tight relationship between the gender medians for serum sodium is only possible when raw laboratory data are used for calculation. The two patient medians can be used to confirm both and are useful as independent estimates of analytical bias during constant calibration periods. In contrast to the gender combined median, the estimate of analytical bias can be confirmed further by calculation of the ratios of medians for males and females.</jats:sec

    Participation in introductory APIB training at the Colorado NIDCAP Center-Report on the training and its applicability to future studies-

    Get PDF
    本研修の目的は,新生児・早産児行動評価(Assessment of Term and Preterm Infant Behavior:APIB 1))を研究に活用するため,その具体的な方法を学ぶことであった.今回,国際NIDCAP®連盟(Newborn Individualized Developmental Care and Assessment Program FederationInternational:NFI)が認定する公式のトレーニング施設,Colorado NIDCAPセンターにおいて,2013年9月7日~8日の2日間,APIBの導入研修に参加する機会を得た.NFIは米国マサチューセッツ州ボストンに本部を置き,北米,南米,ヨーロッパに20のトレーニング施設を認定し,包括的で質の高いトレーニングとコンサルテーションの機会を提供している.APIBは,正期産児を対象とする新生児行動評価(Neonatal Behavioral Assessment Scale:NBAS 2))を,早産児と発達上のリスクを持つ新生児に適合するように開発された評価法であり,新生児と観察者の相互作用を通して,中枢神経系の組織化の状態と受け入れられる刺激を評価し,発達の評価や発達支援の方策を考案するために用いられている.APIBを研究に活用する際は,評価者としての認定が必要であり,トレーニングは「準備の段階」「導入トレーニング」「自主トレーニングおよび指導者との調整(中間評価)」「信頼性の評価」の4段階からなる.今回参加した導入研修では,APIBの基盤となる理論と実際の評価法を学び,評価の進め方とスコア化の基準を理解するとともに,早産児の現在の状態と受け入れられる刺激を評価することの重要性を知ることができた.本稿では,研修内容および今後の研究への活用性について報告する

    Biofluid Diagnostics by FTIR Spectroscopy: A Platform Technology for Cancer Detection

    Get PDF
    Fourier Transform Infrared Spectroscopy (FTIR) has been largely employed by scientific researchers to improve diagnosis and treatment of cancer, using various biofluids and tissues. The technology has proved to be easy to use, rapid and cost-effective for analysis on human blood serum to discriminate between cancer versus healthy control samples. The high sensitivity and specificity achievable during samples classification aided by machine learning algorithms, offers an opportunity to transform cancer referral pathways, as it has been demonstrated in a unique and recent prospective clinical validation study on brain tumours. We herein highlight the importance of early detection in cancer research using FTIR, discussing the technique, the suitability of serum for analysis and previous studies, with special focus on pre-clinical factors and clinical translation requirements and development

    Proteomic Analyses Reveal High Expression of Decorin and Endoplasmin (HSP90B1) Are Associated with Breast Cancer Metastasis and Decreased Survival

    Get PDF
    BACKGROUND: Breast cancer is the most common malignancy among women worldwide in terms of incidence and mortality. About 10% of North American women will be diagnosed with breast cancer during their lifetime and 20% of those will die of the disease. Breast cancer is a heterogeneous disease and biomarkers able to correctly classify patients into prognostic groups are needed to better tailor treatment options and improve outcomes. One powerful method used for biomarker discovery is sample screening with mass spectrometry, as it allows direct comparison of protein expression between normal and pathological states. The purpose of this study was to use a systematic and objective method to identify biomarkers with possible prognostic value in breast cancer patients, particularly in identifying cases most likely to have lymph node metastasis and to validate their prognostic ability using breast cancer tissue microarrays. METHODS AND FINDINGS: Differential proteomic analyses were employed to identify candidate biomarkers in primary breast cancer patients. These analyses identified decorin (DCN) and endoplasmin (HSP90B1) which play important roles regulating the tumour microenvironment and in pathways related to tumorigenesis. This study indicates that high expression of Decorin is associated with lymph node metastasis (p&lt;0.001), higher number of positive lymph nodes (p&lt;0.0001) and worse overall survival (p = 0.01). High expression of HSP90B1 is associated with distant metastasis (p&lt;0.0001) and decreased overall survival (p&lt;0.0001) these patients also appear to benefit significantly from hormonal treatment. CONCLUSIONS: Using quantitative proteomic profiling of primary breast cancers, two new promising prognostic and predictive markers were found to identify patients with worse survival. In addition HSP90B1 appears to identify a group of patients with distant metastasis with otherwise good prognostic features
    corecore